This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 0% and 6.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed (CHE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 1.70% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Option Care Health, LifeStance Health, Addus HomeCare and Pennant
by Zacks Equity Research
Option Care Health, LifeStance Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch Amid a Challenging Outpatient Home Health Industry
by Zacks Equity Research
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. OPCH, LFST, ADUS and PNTG are well poised to gain from the prospects.
LifeStance Health Group (LFST) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 26.67% and 0.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Oak Street Health, Inc. (OSH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of 11.11% and 1%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 5.45% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of -58.33% and 1.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -3.23% and 1.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health (LFST) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
LifeStance Health (LFST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.